LXRX — Lexicon Pharmaceuticals Balance Sheet
0.000.00%
- $472.42m
- $412.98m
- $31.08m
- 33
- 18
- 99
- 48
Annual balance sheet for Lexicon Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 152 | 86.7 | 138 | 170 | 238 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.395 | 0.014 | 0.028 | 1.01 | 3.47 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 158 | 88.9 | 141 | 177 | 246 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.5 | 3.48 | 4.37 | 7.51 | 7.32 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 204 | 137 | 194 | 229 | 298 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 46.8 | 22.1 | 23.2 | 31.5 | 45.2 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 47.4 | 23.3 | 77.2 | 136 | 152 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 156 | 114 | 117 | 93.1 | 146 |
| Total Liabilities & Shareholders' Equity | 204 | 137 | 194 | 229 | 298 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |